Moderna (MRNA) Stock
Key stats
- Market cap
- $83.68B
- Price / Earnings ratio
- -30.0x
- EPS (TTM)
- -$7.08
- Volume
- Loading
- 52-week high
- $280.80
- 52-week low
- $22.28
- EPS vs analyst estimate
- +76.5%Q3 FY25 · -$0.51 vs -$2.17
Source: third-party data provider, as of November 19, 2026
EPS estimate: analyst consensus
Compare with MRNA
Recent news

SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here
SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here
MRNA

Is Moderna's Cancer Vaccine a Game Changer for the Stock?
Is Moderna's Cancer Vaccine a Game Changer for the Stock?
MRNA

Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
MRNA

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls
Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls
MRNA
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 41.45
- MACD 12/26/9
- 3.18
- EMA 9 of MACD
- 9.88
- MACD histogram
- -6.69
- SMA 50
- $205.61
- Price below SMA 50
- EMA 50
- $201.54
- Price below EMA 50
- SMA 200
- $98.86
- Price above SMA 200
- EMA 200
- $116.38
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 18, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 12 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.93 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here
SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here
MRNA

Is Moderna's Cancer Vaccine a Game Changer for the Stock?
Is Moderna's Cancer Vaccine a Game Changer for the Stock?
MRNA

Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
MRNA

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls
Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls
MRNA

Moderna Targets 2027 Cancer Therapy Launch, Raises 2026 Revenue Growth Outlook
Moderna Targets 2027 Cancer Therapy Launch, Raises 2026 Revenue Growth Outlook
MRNA

MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?
MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?
MRNA

Why Moderna Stock Dropped on Thursday
Why Moderna Stock Dropped on Thursday
MRNA

Why Did U, MRNA, ABNB Stocks Surge To 52-Week Highs Today?
Why Did U, MRNA, ABNB Stocks Surge To 52-Week Highs Today?
MRNA

Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy
Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy
MRNA

Can Moderna's First Cancer Therapy Win FDA Approval in 2027?
Can Moderna's First Cancer Therapy Win FDA Approval in 2027?
MRNA
News tone: automated (AI) classification of the article's content, not a price prediction.
About Moderna
Since our founding in 2010, we have worked to build the industry's leading messenger RNA (mRNA) technology platform, the infrastructure to accelerate drug discovery and early development, a rapidly expanding pipeline, and a world-class team. Our pipeline includes development candidates for mRNA-based vaccines and therapies spanning several therapeutic areas, and we have multiple clinical trials underway with other development candidates progressing toward the clinic.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Stéphane Bancel M.B.A. | CEO & Director | 1973 |
| Mr. James M. Mock | Chief Financial Officer | 1977 |
| Mr. Juan Andres | Chief Operating Officer | 1965 |
| Dr. Stephen Hoge M.D. | President | 1976 |
| Ms. Shannon Thyme Klinger J.D. | Chief Legal Officer & Corporate Secretary | 1971 |
| Ms. Lavina Talukdar CFA | Senior VP & Head of Investor Relations | 1974 |
| Chris Ridley | VP & Global Head of Communications | — |
| Ms. Tracey Franklin | Chief People & Digital Technology Officer | 1980 |
| Dr. Charbel Haber M.P.H., Ph.D. | Senior VP & Head of Global Regulatory Science | — |
| Mr. Patrick Norman Bergstedt | Senior Vice President of Commercial Vaccines | 1962 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 19, 2026
Technical indicators
- RSI 14
- 41.45
- MACD 12/26/9
- 3.18
- EMA 9 of MACD
- 9.88
- MACD histogram
- -6.69
- SMA 50
- $205.61
- Price below SMA 50
- EMA 50
- $201.54
- Price below EMA 50
- SMA 200
- $98.86
- Price above SMA 200
- EMA 200
- $116.38
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 18, 2026. Technical data, not a recommendation.
Analyst views
12 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $80.00
- Average
- $150.80
- High
- $305.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +24.7 | -18.2 | ||||||||||
| 2022 | -28.0 | -11.1 | +15.2 | -23.9 | +2.3 | -0.4 | +9.4 | -18.1 | -14.9 | +24.2 | +13.8 | -1.0 |
| 2023 | -1.6 | -20.4 | +13.2 | -16.7 | -4.3 | -5.5 | -3.3 | -0.8 | -8.2 | -26.5 | +2.0 | +24.6 |
| 2024 | -10.2 | -6.8 | +12.1 | +4.5 | +27.9 | -19.7 | +2.8 | -17.8 | -8.4 | -15.0 | -21.2 | -6.1 |
| 2025 | -6.1 | -15.3 | -6.3 | +5.1 | -1.7 | +2.0 | +3.0 | -12.7 | +6.8 | -1.6 | +4.3 | +22.1 |
| 2026 | +42.8 | +25.9 | -3.9 | -8.2 | +4.0 | +52.0 | -24.4 | +154.5 | +24.8 | +17.3 | -10.9 |



